Last reviewed · How we verify
group V
Group V, marketed by Seoul National University Hospital, holds a niche position in its therapeutic area with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the protection offered by its patent. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | group V |
|---|---|
| Sponsor | Seoul National University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The RECLAIM Study. (NA)
- Conventional vs Pulsed RF in Coccydynia (NA)
- V-CARE (Virtual Care After REsuscitation) (NA)
- ILUMIEN-V - AERO: All-comEr Registry of OCT (AERO)
- Efficacy Evaluation of Electroacupuncture in the Treatment of Functional Dyspepsia (NA)
- Safety and Effectiveness of Physician-Modified Fenestrated and Branched Aortic Endografting for the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms (NA)
- Temporal Interference Stimulation for Social Cognition (NA)
- A Graphene Far-infrared Intervention Study of Cognitive Status in Older Adults (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- group V CI brief — competitive landscape report
- group V updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI